CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This study is to determine the maximum tolerated dose(MTD), dose limiting toxicity(DLT),
safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in Combination
with Bortezomib and Dexamethasone in patients with Previously Treated Multiple Myeloma.